Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
72
Frequently Asked Questions
What is Market Cap of Unum Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Unum Therapeutics Inc market cap is $105.32M.
What is the 52-week high for Unum Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Unum Therapeutics Inc 52 week high is $3.72 as of September 06, 2025.
What is the 52-week low for Unum Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Unum Therapeutics Inc 52 week low is $0.295 as of September 06, 2025.
What is Unum Therapeutics Inc stock price today?
Unum Therapeutics Inc stock price today is $2.50.
What was Unum Therapeutics Inc stock price yesterday?
Unum Therapeutics Inc stock price yesterday was $2.53.
What is the PE ratio of Unum Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Unum Therapeutics Inc’s P/E ratio is None.
What is the Price-to-Book ratio of Unum Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Unum Therapeutics Inc P/B ratio is 4.0165.
What is Unum Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Unum Therapeutics Inc's EBITDA is 0.08.
What is the 50-day moving average of Unum Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Unum Therapeutics Inc 50-day moving average is $2.61.
How many employess does Unum Therapeutics Inc has?
